INTERNATIONAL PATENT: GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD., 标新生物医药科技（上海）有限公司 FILES APPLICATION FOR "COMPOUND DESIGNED ON BASIS OF CRBN E3 UBIQUITIN LIGASE AND USE OF COMPOUND"

Posted On: 2025-11-17

GENEVA, Nov. 17 -- GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (Room 101, Building 20, Lane 218, Haiji 6th Road, Lingang Special Area, China (Shanghai) Pilot Free Trade ZonePudong New Area, Shanghai 201306), 标新生物医药科技（上海）有限公司 (中国上海市浦东新区自由贸易试验区临港新片区海基六路218弄20号101室) filed a patent application (PCT/CN2025/090856) for "COMPOUND DESIGNED ON BASIS OF CRBN E3 UBIQUITIN LIGASE AND USE OF COMPOUND" on Apr 24, 2025. With publication no. WO/2025/23255...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

INTERNATIONAL PATENT: GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD., 标新生物医药科技（上海）有限公司 FILES APPLICATION FOR "COMPOUND DESIGNED ON BASIS OF CRBN E3 UBIQUITIN LIGASE AND USE OF COMPOUND"